Comparison of Hematologic Changes between Rivaroxaban and Aspirin for Venous Thromboembolism Prophylaxis after Total Knee Arthroplasty.
10.4055/jkoa.2012.47.6.410
- Author:
Moo Ho SONG
1
;
Bu Hwan KIM
;
Seong Jun AHN
;
Seong Ho YOO
;
Yeong Joon KIM
Author Information
1. Department of Orthopaedic Surgery, Daedong General Hospital, Busan, Korea. mhsong21@hanmail.net
- Publication Type:Original Article
- Keywords:
arthroplasty;
knee;
venous thromboembolism;
Rivaroxaban;
Aspirin
- MeSH:
Arthroplasty;
Aspirin;
Hemoglobins;
Humans;
Knee;
Morpholines;
Thiophenes;
Venous Thromboembolism;
Rivaroxaban
- From:The Journal of the Korean Orthopaedic Association
2012;47(6):410-415
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To compare the hematologic changes and the rates of transfusion of patients using rivaroxaban or aspirin for venous thromboembolism prophylaxis after a total knee arthroplasty. MATERIALS AND METHODS: Among patients with total knee arthroplasty from July 2010 to March 2011, two groups of 100 consecutive cases were enrolled in this study, 50 patients with Rivaroxaban group and 50 patients with Aspirin group for venous thromboembolism prophylaxis after a total knee arthoplasty. Hematologic changes and transfusion rates were calculated in each group. RESULTS: The mean of decreased hemoglobin was 4.7 (3.1-6.6) in the Rivaroxaban group and 3.6 (2.0-5.1) in the Aspirin group (p<0.05). The number of patients with decreased hemoglobin of less than 8 g/dl was observed in 23 cases (46%) in the Rivaroxaban group, and 9 cases (18%) in the Aspirin group. The numbers of patients who needed transfusion were 12 in the Rivaroxaban group, and 2 in the Aspirin group (p<0.05). CONCLUSION: Rivaroxaban group revealed more significant decrease of hemoglobin and needed more transfusion than the Aspirin group did. For the prevention of venous thromboembolism after total knee arthroplasty, we should be careful using Rivaroxaban for the standard risk patients of venous thromboembolism.
